Development of an Effective Immune Response in Adults With Down Syndrome After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination. (29th July 2022)

• Record Type: Journal Article
• Authors: Esparcia-Pinedo, Laura; Yarci-Carrión, Ayla; Mateo-Jiménez, Gloria; Ropero, Noelia; Gómez-Cabañas, Laura; Lancho-Sánchez, Ángel; Almendro-Vázquez, Patricia; Martín-Gayo, Enrique; Paz-Artal, Estela; Sanchez-Madrid, Francisco; Moldenhauer, Fernando; Gutiérrez-Cobos, Ainhoa; Real de Asúa, Diego; Alfranca, Arantzazu
• Is Part Of: Clinical infectious diseases. Volume 76:Number 3(2023)
• Page Start: e155
• Page End: e162
• Publication Date: 2022-07-29
• Subjects: Down syndrome -- COVID-19 -- SARS-CoV-2 -- vaccination -- immune system; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciac590
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Background: Immune dysregulation in individuals with Down syndrome (DS) leads to an increased risk for hospitalization and death due to coronavirus disease 2019 (COVID-19) and may impair the generation of protective immunity after vaccine administration. Methods: The cellular and humoral responses of 55 individuals with DS who received a complete SARS-CoV-2 vaccination regime at 1 to 3 (visit [V 1]) and 6 (V2) months were characterized. Results: SARS-CoV-2–reactive CD4+ and CD8+ T lymphocytes with a predominant Th1 phenotype were observed at V1 and increased at V2. Likewise, an increase in SARS-CoV-2–specific circulating Tfh (cTfh) cells and CD8+ CXCR5+ PD-1hi lymphocytes was already observed at V1 after vaccine administration. Specific immunoglobulin G (IgG) antibodies against SARS-CoV-2 S protein were detected in 96% and 98% of subjects at V1 and V2, respectively, although IgG titers decreased significantly between both time points. Conclusions: Our findings show that DS individuals develop an effective immune response to usual regimes of SARS-CoV-2 vaccination. Abstract : The work shows the cellular and humoral responses to SARS-CoV-2 vaccination of individuals with Down syndrome (DS) after 1 to 3 (V1) and 6 (V2) months. An effective immune response after 6 months was observed in 98% of DS individuals.